Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fortunato Morabito

Showing results (1-10 of 302) with videos related to

Pageof 31
Sort By:
Expert Opinion on Biological Therapy|December 2, 2014
Autologous stem cell transplantation in multiple myeloma is not dead but alive and wellMassimo Martino, Fortunato Morabito
Current Cancer Drug Targets|June 8, 2012
Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millenniumFortunato Morabito, Anna Grazia Recchia, Carla Mazzone, et al.
Expert Opinion on Emerging Drugs|August 28, 2012
Emerging biological insights and novel treatment strategies in multiple myelomaMassimo Gentile, Anna Grazia Recchia, Carla Mazzone, et al.
Leukemia & Lymphoma|June 12, 2015
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the targetFortunato Morabito, Massimo Gentile, John F Seymour, et al.
Clinical Rheumatology|July 1, 2005
Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: report of two casesPaola L Minciullo, Fortunato Morabito, Rosalba Mandaglio, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 20, 2025
Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic CriteriaEnrica Antonia Martino, Giuseppe Mele, Ernesto Vigna, et al.
Haematologica|February 12, 2002
Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucilFortunato Morabito, Massimo Mangiola, Caterina Stelitano, et al.
Leukemia & Lymphoma|November 17, 2006
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapyVincenzo Callea, Maura Brugiatelli, Caterina Stelitano, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysisStefano Molica, Diana Giannarelli, Luciano Levato, et al.
Expert Opinion on Investigational Drugs|March 22, 2016
Sorafenib for the treatment of multiple myelomaMassimo Gentile, Massimo Martino, Anna Grazia Recchia, et al.
Pageof 31

Showing results (1-10 of 302) with videos related to

Sort By:
Pageof 31
Expert Opinion on Biological Therapy|December 2, 2014
Autologous stem cell transplantation in multiple myeloma is not dead but alive and wellMassimo Martino, Fortunato Morabito
Current Cancer Drug Targets|June 8, 2012
Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millenniumFortunato Morabito, Anna Grazia Recchia, Carla Mazzone, et al.
Expert Opinion on Emerging Drugs|August 28, 2012
Emerging biological insights and novel treatment strategies in multiple myelomaMassimo Gentile, Anna Grazia Recchia, Carla Mazzone, et al.
Leukemia & Lymphoma|June 12, 2015
Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the targetFortunato Morabito, Massimo Gentile, John F Seymour, et al.
Clinical Rheumatology|July 1, 2005
Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: report of two casesPaola L Minciullo, Fortunato Morabito, Rosalba Mandaglio, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 20, 2025
Refining High-Risk Multiple Myeloma: Advancements in Genomic, Clinical, and Prognostic CriteriaEnrica Antonia Martino, Giuseppe Mele, Ernesto Vigna, et al.
Haematologica|February 12, 2002
Peripheral blood CD38 expression predicts time to progression in B-cell chronic lymphocytic leukemia after first-line therapy with high-dose chlorambucilFortunato Morabito, Massimo Mangiola, Caterina Stelitano, et al.
Leukemia & Lymphoma|November 17, 2006
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapyVincenzo Callea, Maura Brugiatelli, Caterina Stelitano, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysisStefano Molica, Diana Giannarelli, Luciano Levato, et al.
Expert Opinion on Investigational Drugs|March 22, 2016
Sorafenib for the treatment of multiple myelomaMassimo Gentile, Massimo Martino, Anna Grazia Recchia, et al.
Pageof 31